# Lexeo Therapeutics, Inc. (LXEO)

> Source: Nexqual · https://nexqual.com/LXEO · data as of 2026-11-18 21:00 UTC · cite as "Nexqual, Lexeo Therapeutics, Inc. (LXEO), nexqual.com/LXEO" · informational, not investment advice.

**Price:** USD 2.95 (+3.33% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 2.86 · day 2.76–3.09 · 52w 2.55–10.99 · market cap $244M · NGM

## Key facts
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $323K; 9 not under a Rule 10b5-1 plan ($323K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 25.11 (range 9–42).
- Total return with dividends: 1Y -67.0% vs S&P 500 +11.4%; 5Y -69.8% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: LXEO paid no cash dividend in the last five years.
- Short interest: 23.98% of float (as of 2026-10-30), 10.5 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $654K | — | — | — | — |
| Operating income | -$60.5M | -$68.5M | -$106M | -$109M | -$114M |
| Net income | -$59.3M | -$66.4M | -$98.3M | -$100.0M | -$105M |
| EPS (diluted) | -$36.36 | -$12.40 | -$3.09 | -$1.86 | — |
| Free cash flow | -$55.2M | -$59.6M | -$81.6M | -$99.0M | -$87.7M |
| Operating margin | -9252.1% | — | — | — | — |
| Net margin | -9063.8% | — | — | — | — |
| Cash + short-term investments | $77.3M | $121M | $129M | $182M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/B 1.2x · FCF yield -34.97% · Earnings yield -41.97%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Tamayo Louis Edward | Chief Financial Officer | 4,117 | $20K | 4.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Townsend Richard Nolan | Chief Executive Officer | 3,345 | $17K | 0.9% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Otero Jose Manuel | Chief Operating Officer | 1,304 | $6K | 0.9% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Tamayo Louis Edward | Chief Financial Officer | 4,641 | $21K | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Otero Jose Manuel | Chief Operating Officer | 4,666 | $21K | 3.3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Bhalla Narinder Pal | Chief Medical Officer | 22,306 | $99K | 21.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Townsend Richard Nolan | Chief Executive Officer | 25,947 | $116K | 6.4% | No | Too little history (no open-market trades in 2023) |
| 2026-05-18 | Otero Jose Manuel | Chief Operating Officer | 1,302 | $7K | 1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-18 | Townsend Richard Nolan | Chief Executive Officer | 3,342 | $17K | 1% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 25.11 (low 9, high 42).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-12 | Cantor Fitzgerald | Reiterated | Overweight | $23 |
| 2026-09-23 | Leerink Partners | Maintained | Outperform | $15 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2023-10-30) |
|---|---|---|
| Total return | -67.0% | -69.8% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | -67.0% | -32.5% |
| Volatility (annualized) | 73.9% | 102.5% |
| Max drawdown | -75.3% (Dec 2025→Oct 2026) | -88.8% (Jul 2024→Apr 2025) |

## Dividends
LXEO paid no cash dividend in the last five years.

## Short interest
17,037,063 shares sold short, 23.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 19,246,976 shares (-11.5%). Days to cover: 10.5 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.81 +1.04% · BLTE (Belite Bio, Inc) USD 156.23 -0.94% · ORKA (Oruka Therapeutics, Inc.) USD 95.74 -0.60% · IBRX (ImmunityBio, Inc.) USD 6.7 +7.03% · IMVT (Immunovant, Inc.) USD 33.17 -0.12% · CGON (CG Oncology, Inc.) USD 80 +1.34%

## More
Full page: https://nexqual.com/LXEO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in LXEO's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Solid Biosciences Inc. (SLDB) | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Bioscien…" |
| Partner | Voyager Therapeutics, Inc. (VYGR) | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Bioscien…" |
| Partner | NEUROCRINE BIOSCIENCES INC (NBIX) | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Bioscien…" |
| Partner | Larimar Therapeutics, Inc. (LRMR) | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Bioscien…" |
| Partner | PTC THERAPEUTICS, INC. (PTCT) | "With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Bioscien…" |
| Partner | Cornell University and Adverum Biotechnologies | "In January 2021, we entered into a license agreement with Adverum, which we amended in February 2022 pursuant to the First Amendment to the Adverum Agreement, such agreement as amended, the Amended Adverum Agreement." |
| Partner | Stelios Therapeutics | "The net decrease of $10.3 million in total research and development expenses for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to decreases in (i) milestone expenses of $…" |
| Partner | Johnson & Johnson (JNJ) | "Abiomed, Inc. (Johnson & Johnson subsidiary)—In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of g…" |

## Company outlook (8-K filed 2026-11-16)

- "Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK – November 16, 2026 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.35 | $-0.33 | −$0.02 | $0 | 7 |
| Next quarter (ends 2027-03-31) | $-0.36 | $-0.34 | −$0.02 | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.34 | $-1.20 | −$0.14 | $0 | 6 |
| Next fiscal year (ends 2027-12-31) | $-1.44 | $-1.38 | −$0.06 | $0 | 8 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 314.0% | ±99.5% |
| 2026-12-18 | 30 | 68.8% | ±19.4% |
| 2027-02-19 | 93 | 74.3% | ±123.8% |
| 2027-05-21 | 184 | 388.0% | ±37.3% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.43 | −$0.32 | Miss −34.4% | -0.5% |
| Aug 12, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.28 | Miss −7.1% | +3.8% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.25 | −$0.30 | Beat +16.7% | -2.2% |
| Mar 30, 2026 | Quarter ended Dec 31, 2025 | −$0.27 | −$0.30 | Beat +10.0% | +5.1% |
| Nov 5, 2025 | — | — | — | — | +0.8% |
| Oct 17, 2025 | — | — | — | — | +5.1% |
| Aug 14, 2025 | — | — | — | — | +0.0% |
| May 12, 2025 | — | — | — | — | +5.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | Schedule 13G/A | OrbiMed Advisors LLC, OrbiMed Capital LLC: 3.9% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000094787126001037/0000947871-26-001037-index.htm |
| 2026-11-16 | Schedule 13G/A | Vestal Point Capital, LP, Ryan Wilder: 6.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000090266426004577/0000902664-26-004577-index.htm |
| 2026-11-16 | Schedule 13G/A | Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 0.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000110465926128311/0001104659-26-128311-index.htm |
| 2026-11-16 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 7.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000127417326000240/0001274173-26-000240-index.htm |
| 2026-11-16 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1907108/000119312526462020/0001193125-26-462020-index.htm |
| 2026-11-16 | 8-K | Quarterly results; Regulation FD disclosure; Other material event — “In the press release described in Item 2.02 above, the Company announced positive interim Phase I/II clinical data and regulatory updates for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (" PKP2-ACM "). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on November 16, 2026 to discuss the interim Phase I/II clinical data of LX2020 for the treatment of PKP2-ACM. Also on November 16, 2026, the Company posted on its…” | https://www.sec.gov/Archives/edgar/data/1907108/000119312526462015/0001193125-26-462015-index.htm |
| 2026-11-16 | Schedule 13G/A | BALYASNY ASSET MANAGEMENT L.P., BAM GP LLC: 10.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000117266126005050/0001172661-26-005050-index.htm |
| 2026-11-13 | Schedule 13G/A | Affinity Asset Advisors, LLC, Michael Cho: 9.8% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000101143826000696/0001011438-26-000696-index.htm |
| 2026-11-10 | Schedule 13G | STATE STREET CORPORATION: 4.4% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1907108/000009375126000685/0000093751-26-000685-index.htm |
| 2026-10-13 | Schedule 13G | passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1907108/000001961726000349/0000019617-26-000349-index.htm |
| 2026-09-29 | 8-K | Completed an acquisition or sale of assets; Unregistered sale of shares | https://www.sec.gov/Archives/edgar/data/1907108/000119312526407555/0001193125-26-407555-index.htm |
| 2026-09-22 | 8-K | Entered a material agreement; Other material event | https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/0001193125-26-397221-index.htm |
| 2026-08-14 | Schedule 13G | passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1907108/000094787126000801/0000947871-26-000801-index.htm |
| 2026-08-14 | Schedule 13G/A | passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1907108/000110465926097207/0001104659-26-097207-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
